Results 51 to 60 of about 8,834,434 (252)

Kappa Opioid Regulation of Stress-Related Behavior [PDF]

open access: yes, 2010
Anxiety disorders affect roughly 40 million American adults in a given year. Those suffering from anxiety disorders often experience additional stress-linked illnesses, such as depression.
Harshberger, Erin
core  

Tramadol Co‐Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Tramadol is frequently co‐prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid‐sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted a secondary analysis of the multicenter IGNITE ADOPT‐PGx pragmatic trial of patients undergoing ...
Noor A. Nahid   +302 more
wiley   +1 more source

Methamphetamine use among people accessing opioid agonist treatment in Australia, 2014 - 2024 [PDF]

open access: yes
This bulletin seeks to explore: i) trends in methamphetamine use among individuals receiving opioid agonist treatment, and ii) whether demographic and treatment characteristics differ among OAT clients who are and are not using ...
Tayeb, Haniene   +2 more
core   +1 more source

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai   +12 more
wiley   +1 more source

Nonclinical human neural new approach methodologies (NAMs): Electrophysiological assessment of opioid agonist and antagonist combination

open access: yesNAM Journal
Background and Purpose: New approach methodologies (NAMs) including microphysiological systems in combination with human induced pluripotent stem cell (hiPSC)-derived neural cells and multielectrode array (MEA) have demonstrated utility for evaluating ...
Carlos Serna, III   +3 more
doaj   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah   +4 more
wiley   +1 more source

The Use of Opioid Agonist Treatment in Critically Ill Patients with Opioid Use Disorder: A Scoping Review

open access: yes, 2023
The objectives of this scoping review are to map the available evidence regarding the use of methadone and buprenorphine as opioid agonist treatment in critically ill patients with opioid use disorder, and to identify knowledge gaps in the existing ...
Kevin Hill   +2 more
core   +1 more source

Repeated activation of delta opioid receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain

open access: yesMolecular Pain, 2016
Despite mu opioid receptor agonists are the cornerstones of moderate-to-severe acute pain treatment, their effectiveness in chronic pain conditions is controversial.
Nunzio Vicario PhD (cand)   +6 more
doaj   +1 more source

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes

open access: yesAddiction Science & Clinical Practice, 2022
Background Virtually delivered healthcare (telehealth, telemedicine) has the potential to reduce gaps in access to opioid agonist therapy (OAT). Barriers to accessing OAT such as lack of transportation, in-person induction requirements, employment ...
Nathaniel Day, Maureen Wass, Kelly Smith
doaj   +1 more source

Measuring the importance of different barriers to opioid agonist treatment using best-worst scaling in an Australian setting

open access: yes, 2023
Measuring the importance of different barriers to opioid agonist treatment using best-worst scaling in an Australian ...
Cathy Mihalopoulos (13063140)   +3 more
core  

Home - About - Disclaimer - Privacy